These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15243967)

  • 1. Editorial comment: HAART and higher hemoglobin levels.
    Moore RD
    AIDS Read; 2004 Jun; 14(6):314-5. PubMed ID: 15243967
    [No Abstract]   [Full Text] [Related]  

  • 2. Anemia in HIV-infected patients receiving highly active antiretroviral therapy.
    Moore RD; Forney D
    J Acquir Immune Defic Syndr; 2002 Jan; 29(1):54-7. PubMed ID: 11782590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: relationships with gender.
    Shah S; Smith CJ; Lampe F; Youle M; Johnson MA; Phillips AN; Sabin CA
    HIV Med; 2007 Jan; 8(1):38-45. PubMed ID: 17305931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal antiretrovirals and hepatic enzyme, hematologic abnormalities among human immunodeficiency virus type 1-uninfected infants: the NISDI perinatal study.
    Mussi-Pinhata MM; Rego MA; Freimanis L; Kakehasi FM; Machado DM; Cardoso EM; Read JS;
    Pediatr Infect Dis J; 2007 Nov; 26(11):1032-7. PubMed ID: 17984811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment: the stresses on AIDS caregivers in the HAART era.
    Selwyn PA
    AIDS Read; 2004 Oct; 14(10):535. PubMed ID: 15510389
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment: changes in HIV hospitalizations.
    Gebbie KM
    AIDS Read; 2007 Aug; 17(8):400. PubMed ID: 17717883
    [No Abstract]   [Full Text] [Related]  

  • 7. Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy.
    Wood E; Hogg RS; Yip B; Harrigan PR; Montaner JS
    Rev Invest Clin; 2004; 56(2):232-6. PubMed ID: 15377076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aetiological factors related to a positive direct antiglobulin test result in human immunodeficiency virus-infected patients.
    Lai M; d'Onofrio G; Visconti E; Tamburrini E; Cauda R; Leone G
    Vox Sang; 2006 May; 90(4):325-30. PubMed ID: 16635076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial comment: failure of HAART to reconstitute CMV-specific protective immunity.
    Jacobson MA
    AIDS Read; 2005 Apr; 15(4):188. PubMed ID: 15844239
    [No Abstract]   [Full Text] [Related]  

  • 10. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial comment: adjuvant radiotherapy for testicular cancer--balancing cancer treatment with HIV management.
    Krown SE
    AIDS Read; 2004 Apr; 14(4):190. PubMed ID: 15116701
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment: HIV-1 infection and the rheumatic diseases--new issues, new challenges, same old disparities.
    Reveille JD
    AIDS Read; 2004 Apr; 14(4):178-9. PubMed ID: 15116699
    [No Abstract]   [Full Text] [Related]  

  • 13. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
    Loke WC; Spittle MF; Mitchell S; Kulasegaram R
    Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
    Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
    HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral lesions among persons with HIV disease with and without highly active antiretroviral therapy in southern India.
    Umadevi KM; Ranganathan K; Pavithra S; Hemalatha R; Saraswathi TR; Kumarasamy N; Solomon S; Greenspan JS
    J Oral Pathol Med; 2007 Mar; 36(3):136-41. PubMed ID: 17305634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic hepatitis C in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Halota W; Pawłowska M
    Przegl Epidemiol; 2002; 56 Suppl 5():41-5. PubMed ID: 15553071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rapid development of anemia in a HIV-positive patient with alpha-thalassemia after zidovudine therapy].
    Altinbaş A; Ozkaya G; Büyükaşik Y; Unal S
    Mikrobiyol Bul; 2007 Jul; 41(3):473-6. PubMed ID: 17933262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.
    Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Solinas P; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):375-83. PubMed ID: 16584508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
    Kwara A; Flanigan TP; Carter EJ
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
    Kong HH; Myers SA
    Dermatol Ther; 2005; 18(1):58-66. PubMed ID: 15842613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.